Please use this identifier to cite or link to this item:
Title: Causes of synthetic disease-modifying drug discontinuation in rheumatoid arthritis: Data from a large real-life cohort
Authors: GOMIDES, Ana Paula MonteiroALBUQUERQUE, Cleandro Pires deSANTOS, Ana Beatriz VargasAMORIM, Rodrigo Balbino ChavesBERTOLO, Manoel BarrosLOUZADA JUNIOR, PauloSANTOS, Isabela AraujoGIORGI, Rina Dalva NeubarthSACILOTTO, Nathalia de CarvalhoRADOMINSKI, Sebastiao CezarBORGHI, Fernanda MariaGUIMARAES, Maria Fernanda B. ResendePINTO, Maria Raquel da CostaRESENDE, Gustavo GomesBONFIGLIOLI, Karina RossiSILVA, Henrique Carrico daSAUMA, Maria de Fatima Lobato da CunhaSAUMA, Marcel LobatoMEDEIROS, Julia Brito dePEREIRA, Ivanio AlvesCASTRO, Glaucio Ricardo Wernwer deBRENOL, Claiton ViegasXAVIER, Ricardo MachadoMOTA, Licia Maria Henrique daPINHEIRO, Geraldo da Rocha Castelar
Citation: PLOS ONE, v.14, n.3, article ID e0213219, 7p, 2019
Abstract: The treatment of rheumatoid arthritis (RA) has evolved rapidly in recent years. Nonetheless, conventional synthetic disease-modifying drugs (csDMARDs) remain the gold standard for RA treatment. The treatment for RA is expensive and this has a negative impact on public health. Given the low cost of csDMARDs compared to those of other treatment strategies, it is important to manage this type of treatment properly. Information on the duration of use of each drug and the reasons for their discontinuation is relevant to medical practitioners as it could improve the information available regarding side effects and their proper management. Moreover, data from clinical practice in the population can provide health care managers with information for resource allocation and optimization of csDMARD use with a consequent cost reduction in the treatment of RA. In this cross-sectional study, we aimed to describe the use of csDMARDs in public health services in Brazil, emphasizing on the duration of use and reasons for discontinuation of each drug. This study is a part of the REAL, a multicenter project that evaluated Brazilian patients with RA from eleven rheumatology services from August to October 2015. Patients were examined clinically, and an analysis of complementary exams and medical records was performed. A total of 1125 patients were included. 98.5% were women with a median age of 55.6 years. 36% and 90.84% patients were using biological disease-modifying drugs (bDMARDs) and csDMARDs, respectively. The duration of use and doses of each medication and the causes of suspension were analyzed. Most of the patients analyzed in this study were using csDMARDs for prolonged periods and methotrexate showed the longest duration of use. Interruption indexes due to ineffectiveness and side effects were analyzed. The knowledge of common adverse effects may alert attending physicians to the proper management of effective and low-cost therapeutic groups.
Appears in Collections:Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/17

Files in This Item:
File Description SizeFormat 
art_GOMIDES_Causes_of_synthetic_diseasemodifying_drug_discontinuation_in_rheumatoid_2019.PDFpublishedVersion (English)335.83 kBAdobe PDFThumbnail

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.